The management of HIV-hodgkin lymphoma

Michele Spina; Marcus Hentrich; Umberto Tirelli

doi:10.1007/978-3-319-12505-3-18

The management of HIV-hodgkin lymphoma

Michele Spina, Marcus Hentrich, Umberto Tirelli

Centro di Riferimento Oncologico

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Since 1996, the availability of combination antiretroviral therapy (cART) has led to improvements in immune status among HIV-infected persons, reducing AIDS-related morbidity and prolonging survival. However, despite the impact of cART on HIV-related mortality, malignancies remain an important cause of death in the current era. The use of cART was also associated with reduced incidence of the two major AIDS-associated malignancies - Kaposi's sarcoma (KS) and high-grade non-Hodgkin lymphoma (NHL). However, among non-AIDS-defining cancers, an increased risk of Hodgkin lymphoma (HL), anal cancer, lung cancer, and liver cancer has been observed.

Original language	English
Title of host publication	Hodgkin Lymphoma: A Comprehensive Overview, Second Edition
Publisher	Springer International Publishing
Pages	307-318
Number of pages	12
ISBN (Print)	9783319125053, 9783319125046
DOIs	https://doi.org/10.1007/978-3-319-12505-3-18
Publication status	Published - Jan 1 2015

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1007/978-3-319-12505-3-18

Fingerprint Dive into the research topics of 'The management of HIV-hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this

@inbook{11eb780c1ca54553be6cf25539eb9e57,

title = "The management of HIV-hodgkin lymphoma",

abstract = "Since 1996, the availability of combination antiretroviral therapy (cART) has led to improvements in immune status among HIV-infected persons, reducing AIDS-related morbidity and prolonging survival. However, despite the impact of cART on HIV-related mortality, malignancies remain an important cause of death in the current era. The use of cART was also associated with reduced incidence of the two major AIDS-associated malignancies - Kaposi's sarcoma (KS) and high-grade non-Hodgkin lymphoma (NHL). However, among non-AIDS-defining cancers, an increased risk of Hodgkin lymphoma (HL), anal cancer, lung cancer, and liver cancer has been observed.",

author = "Michele Spina and Marcus Hentrich and Umberto Tirelli",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/978-3-319-12505-3-18",

language = "English",

isbn = "9783319125053",

pages = "307--318",

booktitle = "Hodgkin Lymphoma: A Comprehensive Overview, Second Edition",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - The management of HIV-hodgkin lymphoma

AU - Spina, Michele

AU - Hentrich, Marcus

AU - Tirelli, Umberto

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Since 1996, the availability of combination antiretroviral therapy (cART) has led to improvements in immune status among HIV-infected persons, reducing AIDS-related morbidity and prolonging survival. However, despite the impact of cART on HIV-related mortality, malignancies remain an important cause of death in the current era. The use of cART was also associated with reduced incidence of the two major AIDS-associated malignancies - Kaposi's sarcoma (KS) and high-grade non-Hodgkin lymphoma (NHL). However, among non-AIDS-defining cancers, an increased risk of Hodgkin lymphoma (HL), anal cancer, lung cancer, and liver cancer has been observed.

AB - Since 1996, the availability of combination antiretroviral therapy (cART) has led to improvements in immune status among HIV-infected persons, reducing AIDS-related morbidity and prolonging survival. However, despite the impact of cART on HIV-related mortality, malignancies remain an important cause of death in the current era. The use of cART was also associated with reduced incidence of the two major AIDS-associated malignancies - Kaposi's sarcoma (KS) and high-grade non-Hodgkin lymphoma (NHL). However, among non-AIDS-defining cancers, an increased risk of Hodgkin lymphoma (HL), anal cancer, lung cancer, and liver cancer has been observed.

UR - http://www.scopus.com/inward/record.url?scp=84955714319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955714319&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-12505-3-18

DO - 10.1007/978-3-319-12505-3-18

M3 - Chapter

AN - SCOPUS:84955714319

SN - 9783319125053

SN - 9783319125046

SP - 307

EP - 318

BT - Hodgkin Lymphoma: A Comprehensive Overview, Second Edition

PB - Springer International Publishing

ER -